123 related articles for article (PubMed ID: 8751548)
1. Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma.
Hamel NW; Sebo TJ; Wilson TO; Keeney GL; Roche PC; Suman VJ; Hu TC; Podratz KC
Gynecol Oncol; 1996 Aug; 62(2):192-8. PubMed ID: 8751548
[TBL] [Abstract][Full Text] [Related]
2. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW
Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of progesterone receptor immunohistochemistry for lymph node metastases in endometrial carcinoma.
Iwai K; Fukuda K; Hachisuga T; Mori M; Uchiyama M; Iwasaka T; Sugimori H
Gynecol Oncol; 1999 Mar; 72(3):351-9. PubMed ID: 10053107
[TBL] [Abstract][Full Text] [Related]
4. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma.
Oyama T; Osaki T; Nose N; Ichiki Y; Inoue M; Imoto H; Yoshimatsu T; Kodate M; Uramoto H; Mizoue T; Yano K; Yasumoto K
Anticancer Res; 2000; 20(1B):505-10. PubMed ID: 10769714
[TBL] [Abstract][Full Text] [Related]
5. Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma.
Silverman MB; Roche PC; Kho RM; Keeney GL; Li H; Podratz KC
Gynecol Oncol; 2000 Apr; 77(1):1-7. PubMed ID: 10739683
[TBL] [Abstract][Full Text] [Related]
6. Proliferating cell nuclear antigen in endometrial carcinoma: pretreatment identification of high-risk patients.
Garzetti GG; Ciavattini A; Goteri G; De Nictolis M; Romanini C
Gynecol Oncol; 1996 Apr; 61(1):16-21. PubMed ID: 8626110
[TBL] [Abstract][Full Text] [Related]
7. [Relationship between expressions of p53, c-erbB2 genes, proliferating cell nuclear antigen and prognosis of patients with ovarian epithelial carcinoma].
Li JD; Li MD; Li YF; Huang X; Liu JH; Liu FY; Zhang CQ
Ai Zheng; 2002 Mar; 21(3):292-6. PubMed ID: 12451998
[TBL] [Abstract][Full Text] [Related]
8. Can p53 nuclear over-expression, Bcl-2 accumulation and PCNA status be of prognostic significance in high-risk superficial and invasive bladder tumours?
Plastiras D; Moutzouris G; Barbatis C; Presvelos V; Petrakos M; Theodorou C
Eur J Surg Oncol; 1999 Feb; 25(1):61-5. PubMed ID: 10188857
[TBL] [Abstract][Full Text] [Related]
9. p53 expression as a prognostic indicator of 5-year survival in endometrial cancer.
Geisler JP; Geisler HE; Wiemann MC; Zhou Z; Miller GA; Crabtree W
Gynecol Oncol; 1999 Sep; 74(3):468-71. PubMed ID: 10479512
[TBL] [Abstract][Full Text] [Related]
10. Assessment of inhibin and p53 in granulosa cell tumors of the ovary.
Gebhart JB; Roche PC; Keeney GL; Lesnick TG; Podratz KC
Gynecol Oncol; 2000 May; 77(2):232-6. PubMed ID: 10785470
[TBL] [Abstract][Full Text] [Related]
11. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
12. p53 protein overexpression in early stage endometrial cancer.
Kohlberger P; Gitsch G; Loesch A; Tempfer C; Kaider A; Reinthaller A; Kainz C; Breitenecker G
Gynecol Oncol; 1996 Aug; 62(2):213-7. PubMed ID: 8751552
[TBL] [Abstract][Full Text] [Related]
13. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract][Full Text] [Related]
14. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction.
Ishida H; Irie K; Itoh T; Furukawa T; Tokunaga O
Cancer; 1997 Sep; 80(6):1034-45. PubMed ID: 9305703
[TBL] [Abstract][Full Text] [Related]
15. Immunoexpression of p53 protein and proliferating cell nuclear antigen in penile carcinoma.
Martins AC; Faria SM; Cologna AJ; Suaid HJ; Tucci S
J Urol; 2002 Jan; 167(1):89-92; discussion 92-3. PubMed ID: 11743282
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment assessment of prognostic indicators in endometrial cancer.
Mariani A; Sebo TJ; Katzmann JA; Keeney GL; Roche PC; Lesnick TG; Podratz KC
Am J Obstet Gynecol; 2000 Jun; 182(6):1535-44. PubMed ID: 10871476
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of ploidy, MIB-1 proliferation marker, and p53 in renal cell carcinoma.
Kramer BA; Gao X; Davis M; Hall M; Holzbeierlein J; Tawfik O
J Am Coll Surg; 2005 Oct; 201(4):565-70. PubMed ID: 16183495
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer.
Mell LK; Meyer JJ; Tretiakova M; Khramtsov A; Gong C; Yamada SD; Montag AG; Mundt AJ
Clin Cancer Res; 2004 Aug; 10(16):5546-53. PubMed ID: 15328195
[TBL] [Abstract][Full Text] [Related]
19. Y-box-binding protein-1 expression is not correlated with p53 expression but with proliferating cell nuclear antigen expression in non-small cell lung cancer.
Yoshimatsu T; Uramoto H; Oyama T; Yashima Y; Gu C; Morita M; Sugio K; Kohno K; Yasumoto K
Anticancer Res; 2005; 25(5):3437-43. PubMed ID: 16101161
[TBL] [Abstract][Full Text] [Related]
20. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
